What happened
Church & Dwight Co., Inc. (NYSE: CHD) grew third-quarter organic sales 5.1%, well above its 3% outlook, and raised 2026 sales guidance.
Reported net sales rose 1.0% to $1.60 billion, a $16.5 million gain from a year earlier and better than the company's outlook of a 1% decline. Adjusted earnings per share of $0.92 rose 13.6% and topped the company's outlook. Reported EPS was $0.89, up from $0.75 a year earlier.
The full-year view moved too. Reported 2026 sales growth is now guided to approximately 0.5%, versus a prior range of flat to 1%. Organic growth is guided to approximately 5%, the high end of the prior 4% to 5% range. Adjusted EPS growth is guided to approximately 7%, tighter than the prior 6% to 8%.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Third-quarter net sales | $1.60 billion | from $1.59 billion, +1.0% | SEC 8-K, Exhibit 99.1 |
| Third-quarter organic sales growth | 5.1% | SEC 8-K, Exhibit 99.1 | |
| Third-quarter adjusted EPS | $0.92 | from $0.81, +13.6% | SEC 8-K, Exhibit 99.1 |
| Third-quarter gross margin | 46.8% | from 45.1%, +170 basis points | SEC 8-K, Exhibit 99.1 |
| Nine-month cash from operations | $841 million | from $852 million, -1.3% | SEC 8-K, Exhibit 99.1 |
| New share repurchase authorization | up to $1 billion | SEC 8-K, Exhibit 99.1 |
Read more: Church & Dwight (CHD) company research
Where the growth came from
Portfolio changes explain why reported growth trails organic growth by so much. The filing's reconciliation adds back 6.1 percentage points for divestitures and subtracts 1.9 points for acquisitions.
Volume did the work, rising 4.6%, while price and mix added 0.5%. Every division grew organically: Consumer Domestic 4.4%, Consumer International 7.8% and Specialty Products 5.0%.
Consumer Domestic net sales were $1.23 billion, up 0.4%. The Miss Mouth's acquisition partly offset the sales impact of last year's portfolio actions. Household product sales rose 10.0% while personal care sales fell 10.4%. The company credits domestic organic growth to Arm & Hammer laundry detergent and cat litter, TheraBreath, and Waterpik water flossers.
International net sales were $297 million, up 2.5%. Volume rose 9.1%, but lower price and mix subtracted 1.3%.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
Why it matters
OptimistFi has argued that Church & Dwight works as a defensive compounder if its brands keep shelf space, resist private-label trade-down and turn modest category growth into cash without giving up margin. The quarter strengthens that view on volume and margin.
Margin is the clearest support. Gross margin rose 170 basis points to 46.8%. The filing credits higher volume, productivity, tariff refunds and favorable mix, which offset higher inflation and transportation costs. Adjusted income from operations rose 10.1% to $298 million.
Spending moved in opposite directions. Marketing was 11.9% of net sales, down 90 basis points. Adjusted SG&A rose 110 basis points to 16.3% of net sales, mainly on acquisition-related amortization and expenses, growth investments and higher incentive pay.
Cash conversion is the weaker link. Cash from operations for the first nine months fell 1.3% to $841 million even as net income rose to $631.3 million from $593.3 million. Inventories used $98.2 million of cash in the period.
The company's risk language still lists growing private-label shelf space and online share among factors that could hurt results. It also points to inflationary pressure tied to the Middle East conflict and rising global transportation rates.
What the buyback and balance sheet add
The board approved a program to repurchase up to $1 billion of common stock. The program has no expiration date and replaces the existing one. That amount is a ceiling, not money spent.
Buying has been light this year. The company bought $37.1 million of treasury stock in the first nine months, against $600.0 million a year earlier. Weighted diluted shares in the quarter were 238.7 million, down from 243.2 million.
At Sept. 30, total debt was $2.2 billion and cash was $447 million. Of the debt, $424.7 million is classified as current.
What's next
Church & Dwight said it will give its first formal update on its 2030 growth initiatives at its January investor meeting. Those initiatives focus on expanding Arm & Hammer, increasing TheraBreath in oral care and scaling the international business. The update is the next dated test of whether volume growth of this size can last.
Fourth-quarter guidance sets the near-term bar. The company expects reported sales to fall approximately 0.5%, driven entirely by the 2025 portfolio actions. It expects organic growth of approximately 4.0% and adjusted EPS up 17% to 19%. Full-year cash from operations is guided to approximately $1.18 billion, so the fourth-quarter report needs to deliver cash as well as sales growth. A miss on organic growth or cash would weaken the case.
More from OptimistFi
- CHD stock: research and coverage of Church & Dwight
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
Sources
- Church & Dwight third-quarter 2026 earnings release (Exhibit 99.1 to Form 8-K) — News release dated Oct. 30, 2026 with results, outlook, buyback authorization and financial tables.
- Church & Dwight Form 8-K — Item 2.02 report of results of operations for the quarter ended Sept. 30, 2026.
Explore OptimistFi research on Church & Dwight Co., Inc.: https://optimistfi.com/stocks/CHD
Browse Church & Dwight Co., Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Church & Dwight Co., Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
